logo

Aldeyra Therapeutics, Inc. (ALDX)



Trade ALDX now with
  Date
  Headline
9/26/2018 4:07:13 PM Aldeyra Therapeutics Announces Proposed Public Offering Of Common Stock
9/26/2018 7:03:29 AM Aldeyra Therapeutics Announces Positive Results From Phase 2b Dry Eye Disease Clinical Trial
9/25/2018 8:08:31 AM Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented At IASLC
8/9/2018 7:33:18 AM Aldeyra Therapeutics Q2 Loss Per Share $0.46 Vs Loss $0.35 Last Year
7/31/2018 8:03:52 AM Aldeyra Therapeutics Names Joshua Reed As CFO
7/12/2018 8:05:27 AM Aldeyra Therapeutics Announces Last Patient Dosed In Dry Eye Disease Phase 2b Clinical Trial
4/24/2018 8:04:39 AM Aldeyra Therapeutics Announces First Patient Enrolled In Allergic Conjunctivitis Phase 3 Clinical Trial
3/29/2018 7:37:49 AM Aldeyra Therapeutics FY Net Loss $22.3 Mln Vs Loss $18.7 Mln Last Year
2/21/2018 8:08:38 AM Aldeyra Therapeutics Selected For Podium Presentation Of Phase 2a Dry Eye Disease Results
1/30/2018 8:07:31 AM Aldeyra Therapeutics Enrolls First Patient In Phase 2b Clinical Trial Of Topical Ocular Reproxalap
3/20/2015 9:34:56 AM H.C. Wainwright Reiterates Aldeyra Therapeutics, Inc. (ALDX) At Buy With $14 up from $13 Price Target
  
 
>